SCHEMBL15516697

SCHEMBL15516697

COC(=O)COc1c(C)cc(Br)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
POLB P06746 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 4/20 0.48
CYP1A2 P05177 3/20 0.48
CYP2D6 P10635 1/20 0.48
MMP1 P03956 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
CYP2C19 P33261 1/20 0.46
LMNA P02545 1/20 0.45
FAAH O00519 2/20 0.43
BCHE P06276 2/20 0.43
ACHE P22303 2/20 0.43
TSHR P16473 1/20 0.42
PKM P14618 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20607419 0.89 KMT2A (0.47) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL15516922 0.85 MMP1 (0.48) KMT2AMEN1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL7028752 0.84 ALDH1A1 (0.58) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL8240786 0.84 MEN1 (0.43) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL3681218 0.84 HSP90AB1 (0.47) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL15517469 0.82 LMNA (0.53) KMT2AMEN1POLBALDH1A1KDM4E
SCHEMBL4677835 0.82 MMP1 (0.46) KMT2AMEN1POLBALDH1A1KDM4E
SCHEMBL3190087 0.81 MEN1 (0.59) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL3201351 0.81 KMT2A (0.55) KMT2AMEN1POLBSMN1; SMN2ALDH1A1
SCHEMBL15518130 0.81 KDM4E (0.51) KMT2AMEN1POLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2890677-B1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-11-15 EP disclosed
US-9447083-B2 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-09-20 US disclosed
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-10 US disclosed
EP-2890677-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG Chong Kun Dang Pharmaceutical Corp. (KR) 2015-07-08 EP disclosed
CN-104755460-A N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARM CORP 2015-07-01 CN disclosed
WO-2014035149-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG MALT1, MCL1, ACIN1 KMT2A 355/4885MEN1 3665/4885POLB 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.